Head-to-Head diabetes drug trial seeks better blood sugar control

NCT ID NCT05413369

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study compared the effectiveness and safety of two injectable diabetes treatments, iGlarLixi and IDegAsp, in Chinese adults. The 582 participants had type 2 diabetes that wasn't well controlled with oral medications alone. Over 24 weeks, researchers measured which treatment better lowered long-term blood sugar (HbA1c) and managed weight and low blood sugar risks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational Site Number : 1560001

Beijing, 100853, China
Investigational Site Number : 1560002

Zigong, 643002, China
Investigational Site Number : 1560003

Shanghai, 200040, China
Investigational Site Number : 1560004

Chenzhou, China
Investigational Site Number : 1560005

Zhuzhou, 412007, China
Investigational Site Number : 1560006

Shanghai, China
Investigational Site Number : 1560007

Shanghai, 201700, China
Investigational Site Number : 1560008

Baotou, 014010, China
Investigational Site Number : 1560009

Shenyang, 110004, China
Investigational Site Number : 1560010

Hangzhou, 310014, China
Investigational Site Number : 1560011

Changsha, 410013, China
Investigational Site Number : 1560012

Qinhuangdao, China
Investigational Site Number : 1560013

Tianjin, 300121, China
Investigational Site Number : 1560014

Jinan, 250013, China
Investigational Site Number : 1560015

Xuzhou, China
Investigational Site Number : 1560016

Tianjin, 300052, China
Investigational Site Number : 1560017

Nanjing, China
Investigational Site Number : 1560018

Nanjing, China
Investigational Site Number : 1560019

Beijing, China
Investigational Site Number : 1560020

Shanghai, 200040, China
Investigational Site Number : 1560021

Handan, 056002, China
Investigational Site Number : 1560022

Huizhou, 516001, China
Investigational Site Number : 1560023

Cangzhou, 061000, China
Investigational Site Number : 1560024

Chengdu, 611130, China
Investigational Site Number : 1560025

Harbin, China
Investigational Site Number : 1560026

Yuncheng, 044000, China
Investigational Site Number : 1560027

Beijing, 101200, China
Investigational Site Number : 1560028

Nanjing, 210011, China
Investigational Site Number : 1560029

Guangzhou, 510150, China
Investigational Site Number : 1560030

Foshan, 528399, China
Investigational Site Number : 1560031

Luoyang, 471003, China
Investigational Site Number : 1560032

Yueyang, China
Investigational Site Number : 1560033

Yueyang, 414000, China
Investigational Site Number : 1560034

Zhenjiang, 212001, China
Investigational Site Number : 1560035

Huanggang, 438000, China
Investigational Site Number : 1560036

Zhongshan, China
Investigational Site Number : 1560037

Pingxiang, 337055, China
Investigational Site Number : 1560038

Hohhot, China
Investigational Site Number : 1560039

Lanzhou, 730000, China
Investigational Site Number : 1560040

Jinan, 250012, China
Investigational Site Number : 1560041

Kaifeng, China
Investigational Site Number : 1560042

Xingtai, 054031, China
Investigational Site Number : 1560043

Guangzhou, 510080, China
Investigational Site Number : 1560044

Chongqing, 400010, China
Investigational Site Number : 1560045

Harbin, 150001, China
Investigational Site Number : 1560046

Changchun, 130041, China
Investigational Site Number : 1560047

Tonghua, 130000, China
Investigational Site Number : 1560048

Qingdao, 266042, China
Investigational Site Number : 1560049

Zhengzhou, China
Investigational Site Number : 1560050

Suzhou, China
Investigational Site Number : 1560051

Huzhou, China
Investigational Site Number : 1560052

Changde, 415000, China
Investigational Site Number : 1560053

Dalian, 116011, China
Investigational Site Number : 1560054

Chengdu, 610081, China
Investigational Site Number : 1560055

Huangshi, 435000, China
Investigational Site Number : 1560056

Huai'an, 223300, China
Investigational Site Number : 1560057

Nantong, 226001, China
Investigational Site Number : 1560058

Jingzhou, 434020, China
Investigational Site Number : 1560059

Changchun, 130021, China
Investigational Site Number : 1560060

Lianyungang, 222002, China

Conditions

Explore the condition pages connected to this study.

TYPE 2 DIABETES MELLITUS